Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The present prospective study was designed to compare the effects of administering a daily dose of gonadotrophin releasing hormone (GnRH) antagonist vs. an alternate-day dosage of GnRH agonist on ovarian response and in vitro fertilization (IVF) outcome in patients stimulated with recombinant follicle-stimulating hormone (FSH) and human chorionic gonadotrophin (hCG) microdose.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fertility - Assisted Fertilization Center
• Treatments: Cetrorelix; Deslorelin; Follicle Stimulating Hormone; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• women of good physical and mental health

• under 37 years old, with regular menstrual cycles of 25-35 days

• normal basal FSH and LH levels

• BMI less than 30 kg/m2

• presence of both ovaries and intact uterus

• absence of polycystic ovaries

• endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases

• all patients signed a written informed consent form

• no patient had received any hormone therapy for at least 60 days preceding the study.